Ulcerative Colitis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ...
Johnson & Johnson JNJ has announced the submission of a supplemental biologics license application (sBLA) seeking approval of its immunology medicine, Tremfya, for a new indication — moderately to ...
* GALAPAGOS NV - FILGOTINIB 200 MG DEMONSTRATED GREATER EFFICACY COMPARED WITH PLACEBO IN INDUCTION AND MAINTENANCE OF REMISSION IN SELECTION TRIAL * GALAPAGOS NV - RATES OF ADVERSE EVENTS WERE LOW ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results